Vaccine

© Getty Images

Vaxess announces $9 million in funding for mRNA vaccine patch

By Isabel Cameron

Vaxess Technologies, a life sciences company developing a shelf-stable vaccine patch with potential for self-application, has announced an additional $9 million in venture capital funding, with investors including RA Capital, The Engine, and GHIC, and...

Pic:getty/sohelparvezhaque

FDA decision on Pfizer’s maternal RSV vaccine expected by August

By Rachel Arthur

The US Food and Drug Administration (FDA) has accepted Pfizer’s Biologics License Application (BLA) for its maternal RSV vaccine under priority review. If approved, the vaccine will become the first RSV vaccine for pregnant women to protect against RSV...

Pic:getty/andrewbrookes

Janssen discontinues Phase 3 HIV vaccine trial

By Rachel Arthur

Janssen’s experimental HIV vaccine regimen was found to be safe but ineffective in the Phase 3 Mosaico clinical trial: and as a result the company is discontinuing the study.

Pic:getty/morsaimages

Blue Water Vaccines to develop oral chlamydia vaccine

By Rachel Arthur

Blue Water Vaccines has signed an exclusive, global license agreement for the development of a live attenuated, oral Chlamydia vaccine candidate from The University of Texas Health San Antonio.

Pic:getty/markrubens

BioNTech acquires GMP manufacturing site in Singapore

By Rachel Arthur

BioNTech will create an mRNA facility in Singapore through the acquisition of a Novartis site: which will become its Regional Headquarters and production center for the Asia Pacific region.

Pic:getty/andrewbrookes

FDA expected to make decision on GSK’s RSV vaccine in May

By Rachel Arthur

The US Food and Drug Administration (FDA) has granted Priority Review to GSK’s respiratory syncytial virus (RSV) older adult vaccine candidate with a decision expected in May 2023: which could make it the first vaccine approved against the virus.

© GettyImages/Chee Siong Teh

Earnings miss, lowered outlook for Catalent

By Jane Byrne

Shares of Catalent Inc plunged yesterday after the contract development and manufacturing organization (CDMO) reported fiscal first-quarter profit and revenue that missed expectations. The company also scaled back its full-year outlook.

© GettyImages/skodonnell

Pfizer to raise COVID-19 vaccine price in US

By Jane Byrne

As the US government stops buying COVID-19 shots, Pfizer said the vaccine it developed with BioNTech will be sold for US$110 to US$130 per dose, from as early as the first quarter 2023.